HYDROXYNORKETAMINE ANALOGUES, COMPOSITIONS COMPRISING SAME AND METHODS OF USE THEREOF

Abstract

The present disclosure pertains to amino cyclohexanone compounds, pharmaceutical compositions containing same and methods of treating depression, pain, inflammation, and other clinical indications.

Claims

1-18. (canceled)

19. An amino cyclohexanone compound of Formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof ##STR00019## R.sub.1 is —H, —OH, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5); R.sub.2 is —H, —CN, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5); wherein R.sub.4 and R.sub.5 are independently selected from C.sub.1-C.sub.8 saturated or unsaturated alkyl; when R.sub.1 is —OH, R.sub.2 is —H, and R.sub.3 is ##STR00020## when R.sub.1 is —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5), R.sub.2 is —H, and R.sub.3 is ##STR00021## when R.sub.1 is —H, R.sub.2 is —CN, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5); and R3 is ##STR00022##

20. An amino cyclohexanone compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof selected from the group consisting of Formula (II) to (XIX): ##STR00023## ##STR00024## ##STR00025##

21. A pharmaceutical composition comprising an effective amount of a compound according to claim 19, and a pharmaceutically acceptable carrier.

22. A method of inhibiting N-methyl-D-aspartate (NMDA) receptor activity comprising contacting cells with an effective amount of a compound in accordance with claim 21, thereby inhibiting NMDA receptor activity.

23. A method of modifying endogenous concentrations of D-Serine comprising contacting cells with an effective amount of a compound in accordance with claim 21, thereby modifying endogenous concentrations of D-Serine.

24. A method of stimulating the phosphorylation of mammalian target of rapamycin (mTOR) comprising contacting cells with an effective amount of a compound in accordance with claim 21, thereby stimulating the phosphorylation of mTOR.

25. A method of inhibiting nicotinic acetylcholine receptor (nAChR) activity comprising contacting cells with an effective amount of a compound in accordance with claim 21, thereby inhibiting nAChR activity.

26. A method of inhibiting serine racemase (SR) comprising contacting cells with an effective amount of a compound in accordance with claim 21, thereby inhibiting SR.

27. A method of inhibiting or attenuating proinflammatory agents secretion from immune cells, the method comprises contacting the immune cells with an effective amount of a composition according to claim 21, thereby inhibiting or attenuating proinflammatory agents secretion from the immune cells.

28. The method according to claim 27, wherein the proinflammatory agents are selected from a group consisting of IL-6, TNF-α, IL-8, IL-1β, PGE2, and a combination thereof.

29. A method of treatment of a disease or condition selected from the group consisting of a mental disorder, Alzheimer's dementia, amyotrophic lateral sclerosis, inflammation, and pain, the method comprising administering a composition according to claim 21 to a subject in need of such treatment.

30. The method of claim 29, wherein the pain is selected from the group consisting of complex regional pain syndrome (CRPS), chronic pain, severe pain, migraine, fibromyalgia, rheumatic pain, menstrual pain, and neuropathic pain.

31. The method of claim 29, wherein the inflammation is caused by a pathogen, a trauma, a hazardous substance, or an autoimmune disease.

32. The method of claim 31, wherein the pathogen is selected from the group consisting of a virus, a bacteria, a protozoa, a prion, a viroid, and a fungus.

33. The method of claim 32, wherein the pathogen is a virus.

34. The method of claim 33, wherein the virus is a SARS-CoV-2.

35. The method of claim 29, wherein the inflammation is a hyper-inflammation.

36. The method of claim 29, wherein the mental disorder is selected from the group consisting of bipolar depression, major depressive disorder, persistent depressive disorder, psychotic depression, suicidality, premenstrual dysphoric disorder (PMDD), atypical depression, post partum depression, obsessive compulsive disorder, post-traumatic stress disorder, and schizophrenia.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0042] The present invention pertains to novel amino cyclohexanone compounds and to the use thereof in the treatment of depression, pain (e.g., neuropathic pain), and inflammation.

[0043] (2R,6R)-HNK is a pharmacologically active molecule that exerts therapeutic effect via interaction with several possible receptors, including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and nicotinic acetylcholine receptor. (2R,6R)-HNK interacts with its receptor(s) through hydrogen bonding and hydrophobic interactions.

[0044] The herein inventor devised novel HNK analogs to optimize the pharmacological use and efficacy thereof in the treatment of depression, neuropathic conditions, and inflammation and minimize common side effects associated with ketamine administration.

[0045] Illustrative examples of active agents in accordance with the present disclosure include the following compounds, stereoisomers, and enantiomers thereof:

##STR00005##

within Formula (I), the variables R.sub.1-R.sub.3 carry the definitions set forth below:

[0046] R.sub.1 is —OH, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5), wherein R.sub.4 and R.sub.5 are independently selected from C.sub.1-C.sub.8 saturated or unsaturated alkyl;

[0047] R.sub.2 is H;

[0048] when R.sub.1 is —OH, R.sub.3 is

##STR00006##

[0049] when R.sub.1 is —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5)

[0050] R.sub.3 is

##STR00007##

R.sub.1 may be for example, —SCH.sub.3, —SO.sub.2CH.sub.3, —NHCH.sub.3, or —N(CH.sub.3).sub.2;
The disclosure includes all stereoisomers of compounds of Formula I.
Illustrative examples of active agents in accordance with the present disclosure include the following compounds of Formulas (II) to (XI):

##STR00008## ##STR00009##

[0051] Further illustrative examples of active agents in accordance with the present disclosure include the following compounds, stereoisomers, and enantiomers thereof:

##STR00010##

within Formula (I), the variables R.sub.1-R.sub.3 carry the definitions set forth below:

[0052] R.sub.1 is H;

[0053] R.sub.2 is —CN, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5), wherein R.sub.4 and R.sub.5 are independently selected from C.sub.1-C.sub.8 saturated or unsaturated alkyl;

[0054] R.sub.3 is

##STR00011##

[0055] R.sub.2 may be, for example, —SCH.sub.3, —SO.sub.2CH.sub.3, —NHCH.sub.3, or N(CH.sub.3).sub.2.

[0056] The disclosure includes all stereoisomers of compounds of Formula I. Illustrative examples of active agents in accordance with the present disclosure include the following compounds of Formula (XIV)-(XIX):

##STR00012##

[0057] Without being bound by any theory or mechanism of action, the herein compounds, according to Formula I, exert a biochemical effect by a mechanism including one or more of: inhibiting/blocking the N-methyl-D-aspartate NMDA receptor, inhibiting serine racemase (SR) enzyme activity, activating mTOR signaling pathway, activating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, and inhibiting/blocking nicotinic acetylcholine receptors (nAChR), such as α7 nAChR and α3β4 nAChR. Optionally, administration of the herein disclosed compounds results in a reduction in the intracellular and/or extracellular concentrations of D-serine, a co-agonist of NMDA receptor.

[0058] Optionally, an enhanced efficacy is attributed to an enhanced hydrogen bond donating-accepting property of a substituent at the C2 and/or C5, and/or C6 position on the cyclohexanone ring of the herein compounds according to Formula I. The ability of (2R,6R)-HNK to achieve hydrogen bonding interactions is derived from the NH.sub.2 substituent at C2 and the OH substituent at C6 of the molecule. Both moieties can act as hydrogen bond donors/acceptors. Also, the ability of (2R,6R)-HNK to interact with a hydrophobic cleft or site on the respective receptor(s) and/or enzyme(s) is thought to be based upon the presence of the 2-cholorbenzyl moiety at the C2 position of the molecule. The C2 and C6 carbons in the (2R,6R)-HNK cyclohexanone ring are asymmetric, and the R stereochemical configuration at both sites may contribute to the observed pharmacological activity of the compound. The present compounds are devised to optimize the pharmacological use and efficacy of (2R,6R)-HNK through enhanced hydrogen bond donor/acceptor strength, steric and three-dimensional configurations of the molecules.

[0059] The disclosure also includes compounds and salts of Formula I in which the variables R.sub.1-R.sub.3 carry the following definitions:

[0060] R.sub.1 is —H, —OH, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5),

[0061] R.sub.2 is —H, —CN, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5), and

[0062] R.sub.3 is

##STR00013##

[0063] R.sub.4 and R.sub.5 are independently selected from C.sub.1-C.sub.8 saturated or unsaturated alkyl;

[0064] when R.sub.1 is —OH, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5), R.sub.2 is —H;

[0065] when R.sub.2 is —CN, —N.sub.3, —SR.sub.4, —SO.sub.2R.sub.4, —NHR.sub.4, or —N(R.sub.4R.sub.5), R.sub.1 is —H; and

[0066] when R.sub.1 is —OH, R.sub.3 is not

##STR00014##

[0067] Pharmaceutical Compositions

[0068] Compounds disclosed herein can be administered as the neat chemical, but in certain embodiments, are administered as a pharmaceutical composition. Accordingly, the disclosure provides pharmaceutical compositions including a compound or pharmaceutically acceptable salt of a compound according to Formula I, together with at least one pharmaceutically acceptable carrier. The pharmaceutical composition may contain a compound or salt of any one of Formulas I-XIX as the only active agent. Still, in some embodiments, the composition contains at least one additional active agent.

[0069] The term “carrier” applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which the herein compound or salt of Formulas I-XIX is administered.

[0070] Carriers include excipients and diluents and preferably be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier may be inert, or it may possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the herein compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.

[0071] Classes of carriers include but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents. Some carriers may be listed in more than one class; for example, vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin, talc, and vegetable oils. Optional active agents may be included in a pharmaceutical composition, which does not substantially interfere with the activity of the active agents in accordance with this disclosure.

[0072] “Pharmaceutically acceptable salts” are derivatives of the disclosed compounds, wherein the parent compound is modified by making non-toxic acid or base addition salts thereof, and further refers to pharmaceutically acceptable solvates, including hydrates, of such compounds and such salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid addition salts of basic residues such as amines; alkali or organic addition salts of acidic residues such as carboxylic acids; and the like, and combinations comprising one or more of the foregoing salts. The pharmaceutically acceptable salts include non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, cesium salt, and the like; and alkaline earth metal salts, such as calcium salt, magnesium salt, and the like, and combinations comprising one or more of the foregoing salts.

[0073] Pharmaceutically acceptable organic salts include salts prepared from organic acids such as acetic, trifluoroacetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC—(CH.sub.2)—COOH where n is 0-4, and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, and the like; and amino acid salts such as arginate, asparginate, glutamate, and the like, and combinations comprising one or more of the foregoing salts.

[0074] Methods of Treatment

[0075] In an embodiment of the invention, the herein compounds, according to Formula I, and exemplary Formulas II-XIX are effective in treating central nervous system (CNS) or mental or neurological disorders/conditions/diseases, such as bipolar depression, major depressive disorder, schizophrenia, Alzheimer's dementia, amyotrophic lateral sclerosis, and pain (e.g., complex regional pain syndrome (CRPS), chronic pain, severe pain, migraines, menstrual pain, neuropathic pain, or neuropathic pain).

[0076] The herein methods of treatment comprise administering to a subject in need of such treatment, a pharmaceutical composition comprising a therapeutic effective amount of the herein disclosed compounds according to Formula I. Specific exemplary compounds include compounds II-XIX.

[0077] Accumulating evidence suggests that some patients with severe COVID-19 might experience hyper-inflammation expressed by robust cytokine release (a.k.a., cytokine storm syndrome) or secondary hemophagocytic lymphohistiocytosis (sHLH).

[0078] International patent application No.: PCT/IL2021/050574 to an inventor of the present invention discloses an anti-inflammatory efficacy of HNK. Specifically, HNK was demonstrated to inhibit pro-inflammatory agents release (e.g., IL-6, TNF-α, IL-8, IL-1β, PGE2) from monocytes cells stimulated by lipopolysaccharide (LPS), the content of which is incorporated by reference.

[0079] Thus, the present invention pertaining to HNK analogs further discloses the use of such analogs in the treatment and management of inflammation and particularly in treating subjects afflicted with an infectious disease associated with hyper-inflammation, such as COVID-19.

[0080] Thus, in an embodiment of the invention, the herein compounds, according to Formula I, are further effective in treating subjects afflicted with an infectious disease. In an embodiment of the invention, the herein compounds, according to Formula I, are further effective in treating inflammation. In an embodiment of the invention, the herein compounds, according to Formula I, are further effective in treating inflammation in subjects afflicted with an infectious disease. In an embodiment of the invention, the herein compounds, according to Formula I, are further effective in treating subjects afflicted with a viral disease associated with inflammation. In an embodiment of the invention, the herein compounds, according to Formula I, are effective in the treatment of subjects afflicted with a coronavirus. In an embodiment of the invention, the herein compounds, according to Formula I, are effective in the treatment of subjects afflicted with a SARS-CoV-2. Optionally, the inflammation is a hyper-inflammation.

[0081] As used herein the terms “inhibiting or attenuating” includes but is not limited to any one or more of the following: abrogating, ameliorating, blocking, suppressing, reducing, delaying, halting, alleviating or preventing a certain medical effect (e.g., inhibiting the proinflammatory agents secretion from cells).

[0082] In an embodiment of the invention, the herein compounds, according to Formula, I are also useful in the treatment of conditions associated with both pain and inflammation, including, but not limited to, musculoskeletal conditions, such as arthritis, sports injury, low back pain, menstrual pain, a systemic inflammation, such as autoimmune disease, pericarditis, and pleuritis.

[0083] In an embodiment of the invention, the herein compounds, according to Formula I, are also useful in treating conditions associated with both depression and inflammation, including, but not limited to, chronic arthritis, chronic bowel inflammatory disease, and post major surgery.

[0084] As used herein the term “inflammation” refers to a biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators. The function of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and initiate tissue repair. The herein “inflammation” also encompasses inflammatory conditions considered as “hyper-inflammation”.

[0085] As used herein, the term “hyper-inflammation” refers to syndromes, disorders or conditions caused by severe and uncontrolled immune cell activation and hypercytokinemia (a.k.a., cytokine storm). The clinical presentation of hyper-inflammation inter-alia includes unremitting fever, splenomegaly, coagulopathy, hepatitis, cytopenia, and, if unrestrained, multi-organ failure and death.

[0086] Various physiological conditions may be associated with hyper-inflammation. Non-limited examples of conditions associated with an acute inflammatory response include trauma, hazardous substances, microbial invasion, hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome, sepsis and cytokine release syndrome. Further, non-limited examples of conditions associated with chronic inflammation include autoimmune diseases (e.g., inflammatory bowel disease, psoriasis, etc.).

[0087] As used herein, the term “Cytokine Storm” encompasses a multi-factorial hyper-inflammation associated, inter-alia, with increased expression of one or more of interleukins (IL), chemokines, granulocyte colony-stimulating stimulating factors (G-CSF), and tumor necrosis factor-1α (TNF).

[0088] Thus, an aspect of the invention provides a method of treating a viral infection in a subject in need thereof, the method comprising administering to the subject a therapeutic effective amount of the herein compounds according to Formula I.

[0089] In an embodiment of the invention, the method comprising identifying inflammation/hyper-inflammation in the subject and treating the hyper-inflammation comprising administering to the subject a therapeutic effective amount of the herein compound(s) according to Formula I.

[0090] Identifying inflammation/hyper-inflammation may include assessment of inflammatory markers in a biological sample of a subject, including assessment of increased levels of proinflammatory agents, such as cytokines and chemokines (e.g., the interleukins IL-1b, IL-6, and IL-8, and tumor necrosis factor-1α), C reactive protein (CRP), growth factors (e.g., granulocyte colony-stimulating stimulating factors (G-CSF) and ferritin), and prostaglandins (e.g., PGE2).

[0091] Inflammation/hyper-inflammation can be diagnosed using laboratory methodologies. Non-limited examples of suitable laboratory methodologies include ferritin assessment, platelet count assessment, erythrocyte sedimentation rate determination to identify the subgroup of patients for whom immunosuppression treatment could be effective.

[0092] The herein compounds may be further used to attenuate proinflammatory agent release or secretion from immune cells Immune cells may include neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages, dendritic cells, natural killer cells, and lymphocytes (B cells and T cells). Additional cell types involved in the immune system may be contemplated, such as astrocytes that are crucial regulators of innate and adaptive immune responses in the injured central nervous system. In one embodiment, the immune cells are monocytes. In one embodiment, the immune cells are macrophages. Optionally the immune cells are stimulated/triggered to secrete proinflammatory cytokines by a pathogen, a.k.a., an infectious agent (e.g., Lipopolysaccharides; LPS). The immune cells may be stimulated by a virus, a bacteria, a protozoan, a prion, a viroid, or a fungus. The immune cells may be stimulated, for example, due to an injury, a trauma, an autoimmune disease, a hazardous substance.

[0093] Optionality, a compound(s) as herein disclosed, according to Formula I, will be administered as a single agent or in combination with other drugs including, for example beta2-adrenergic receptor agonists (e.g., metaproterenol, terbutaline, salbutamol, salmeterol, (R,R′)-4′-methoxy-1-naphthylfenoterol); GPR55 receptor antagonists (e.g., cannabidiol, (R,R′)-4′-methoxy-1-naphthylfenoterol), High-mobility group box 1 (HMGB1) protein inhibitors (e.g., heparin and ascorbic acid); Janus kinase (JAK) inhibitors (e.g., tofacitinib, bracicitinib).

[0094] Optionally, a compound(s), as herein disclosed, according to Formula I, may additionally include treatment with steroids, intravenous immunoglobulin, selective cytokine blockade (e.g., anakinra or tocilizumab), and JAK inhibition.

[0095] Optionally, a compound, as herein disclosed, according to Formula I, is used in combination with antimicrobials agents, such as antiviral/antiretroviral agents and antibacterial agents, to thereby manage the symptoms of infections, superinfections, and hyper-inflammation.

[0096] Exemplary antiviral/antiretroviral agents include, without limitation, agents that inhibit viral replication cycle (e.g., agents that inhibit viral DNA polymerase), agents that inhibit viral cell penetration and/or protein synthesis. In an embodiment of the invention, the antiviral/retroviral agent is effective in treating coronavirus infections (e.g., anti-coronavirus antibodies, stem cell-based treatments, etc.).

[0097] Antibacterial agents are typically capable of reducing the metabolic activity of bacteria such that their pathogenic effect in the biological environment will be minimized or eliminated. Exemplary antibiotics include, without limitation, β-Lactam antibiotics (penicillins, cephalosporins, carbapenems, monobactams), Tetracyclines (e.g., doxycycline, minocycline), macrolide antibiotics, aminoglycosides, peptide antibiotics, lincosamides, and streptogramins.

[0098] In an embodiment of the invention, the method comprising identifying patient anxiety and depression associated with hospitalization and social distancing due to SARS-CoV-2 infection using the Hospital Anxiety and Depression Scale (HADS) and treating the anxiety and depression by administering a therapeutic effective amount of a compound(s) according to Formula I.

[0099] As used herein, the term “coronavirus” refers to a family of various viruses, including, without limitation, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS) coronavirus (MERS-CoV), and SARS-CoV-2 (that causes COVID-19).

[0100] The term “therapeutically effective amount” refers to an amount of the active pharmaceutical agent (herein a compound according to Formula I) effective in the treatment of a disease or disorder in a mammal.

[0101] As used herein the term “subject” means any human or non-human animal in need of medical treatment. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. The term “subject” is interchangeable with the term “patient”.

[0102] As used herein the term “prodrug” refers to a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Inactive prodrugs are pharmacologically inactive medications that are metabolized into an active form within the body.

[0103] Methods of treatment in accordance with the present disclosure include administering a compound of Formula I or any combination of compounds of Formula II-XIX.

[0104] Administration of the herein compounds according to Formula I may be before, at the onset of, or following the detection of symptoms (e.g., hyper-inflammation, depression, pain) in the subject.

[0105] Compounds disclosed herein may be administered orally, intravenously, intraperitoneally, topically, parenterally, by inhalation or spray, sublingually, transdermal, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers.

[0106] The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a pill, a capsule, a tablet, a syrup, a transdermal patch, or an ophthalmic solution. Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose. The dosage form may provide immediate release, sustained release, or a combination thereof. Gastro-retentive, intramuscular, subcutaneous, and intraocular dosage forms are also contemplated.

[0107] Methods of treatment in accordance with the present disclosure include methods of treating bipolar depression, major depressive disorder, schizophrenia, Alzheimer's dementia, amyotrophic lateral sclerosis, complex regional pain syndrome (CRPS), chronic pain, or neuropathic pain and/or inflammation by administering a pharmaceutical composition containing an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier to a patient in need of such treatment.

[0108] The compound or salt of Formula I may be the only active agent administered or may be administered together with an additional active agent. For example, the compound of Formula I may be administered together with another active agent.

[0109] Exemplary active agents include, for example, an anti-depressants, such as, escitalopram, fluoxetine, paroxetine, duloxetine, sertraline, citalopram, bupropion, venlafaxine, duloxetine, naltrexone, mirtazapine, venlafaxine, atomoxetine, bupropion, doxepin, amitriptyline, clomipramine, nortriptyline, buspirone, aripiprazole, clozapine, loxapine, olanzapine, quetiapine, risperidone, ziprasidone, carbamazepine, gabapentin, lamotrigine, phenyloin, pregabalin, donepezil, galantamine, memantine, rivastigmine, tramiprosate, or pharmaceutically active salts or prodrugs thereof, or a combination thereof.

[0110] Schizophrenia Medications, include, for example, aripiprazole, lurasidone, asenapine, clozapine, ziprasidone, risperidone, quetiapine, stelazine, olanzapine, loxapine, flupentioxol, perphenazine, haloperidol, chlorpromazine, fluphenazine, prolixin, or paliperidone; Alzheimer's Dementia Medications, such as, for example, donepezil, rivastigmine, galantamine, or memantine.

[0111] ALS Medications, include, for example, riluzole; Pain Medications, such as, for example, acetaminophen, aspirin, NSAIDS, including Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Indomethacin.

[0112] Definitions

[0113] Compounds disclosed herein are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure pertains.

[0114] The terms “a” and “an” do not denote a limitation of quantity but rather denote the presence of at least one of the referenced items.

[0115] The term “chiral” refers to molecules having the property of non-superimposability of the minor image partner.

[0116] “Stereoisomers” are compounds having identical chemical constitution but differ with regard to the arrangement of the atoms or groups in space.

[0117] A “Diastereomer” is a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high-resolution analytical procedures such as electrophoresis, crystallization in the presence of a resolving agent, or chromatography, using, for example, a chiral UPLC column.

[0118] “Enantiomers” refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

[0119] A “racemic mixture” or “racemate” is an equimolar (or 50:50) mixture of two enantiomeric species, devoid of optical activity. A racemic mixture may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0120] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (−) are employed to designate the sign of rotation of plane-polarized light by the compound, with (−) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory.

[0121] Where a compound exists in various tautomeric forms, the disclosure is not limited to any one of the specific tautomers, but rather includes all tautomeric forms.

[0122] The disclosure includes compounds of Formula I having all possible isotopes of atoms occurring in the compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium.

[0123] Certain compounds are described herein using a general formula that includes variables, e.g., R.sub.1, and R.sub.2. Unless otherwise specified, each variable within Formula I is defined independently of other variables. Thus, if a group is said to be substituted, e.g., with 0-2 R*, then said group may be substituted with up to two R* groups, and R* at each occurrence is selected independently from the definition of R*. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0124] The term “substituted” as used herein means that at least one hydrogen on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded. When the substituent is oxo (i.e., =0), then 2 hydrogens on the atom are replaced. When aromatic moieties are substituted by an oxo group, the aromatic ring is replaced by the corresponding partially unsaturated ring. For example, a pyridyl group substituted by oxo is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent.

[0125] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —(CH.sub.2)C3-C7 cycloalkyl is attached through carbon of the methylene (CH.sub.2) group.

[0126] The term “consisting essentially of” means that the composition, or method may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, or method.

[0127] The term “consisting of” means including and limited to.

[0128] As used herein the term “about” refers to ±10% or ±5%.

[0129] The terms “comprise”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.

[0130] The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.

EXAMPLES

[0131] The invention will be described in detail by way of specific examples. The following examples are offered for illustrative purposes and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters, which can be changed or modified to yield essentially the same results. In one or more embodiments, the amounts in the examples should be read with the prefix “about”.

[0132] Methods of Preparing the Present Compounds

[0133] Synthesis of racemic mixture of intermediate 1:

##STR00015##

[0134] The following step is the chiral resolution with L-pyroglutamic acid to provide each enantiomer for further transformation and introduction of —OH group in positions 6 and 5 (4-6 step synthesis).

##STR00016##

[0135] For the molecules with 2,6 substitutions, the inversion of the configuration in position 6 (Mistsunobu type transformation):

##STR00017##

[0136] For the molecules with 2,5 substitutions, the stereoselective epoxidation followed by epoxide ring-opening is conducted.

##STR00018##

Similar derivatization process can be performed to obtain the derivatives of R.sub.2. Products of the herein synthesis are characterized and analyzed by commonly known spectroscopic methods (e.g., H1-NMR, C13-NMR, m.p., IR, Mass-spec).

[0137] Determination of D-Serine Concentrations

[0138] PC-12 cell line (derived from rat adrenal medulla cells) are seeded on 100×20 mm tissue culture plates and maintained at 37° C. under humidified 5% CO.sub.2 in air until they reach >70% confluence. The cells are then incubated for 36 h with media containing the test compounds. The medium is removed, and the cells are assessed for intracellular and extracellular D-serine levels, and expression of serine racemase (SR). All analyses may be repeated in three independent cell cultures (n=3).

[0139] Intracellular D-serine concentrations are measured using capillary electrophoresis-laser induced fluorescence (CE-LIF) method using a P/ACE MDQ system equipped with a laser-induced fluorescence detector (Singh et al., Anal Biochem 2012; 421: 460-466). The extracellular D-serine levels are determined by employing liquid chromatography with mass spectrometric detection (Singh et al., Br J Pharmacol 2015; 172: 4546-59).

[0140] The expression of mSR and dSR in PC-12 cells may be determined using western blotting (Singh et al., Anesthesiology 2014; 121: 149-59). The primary antibody for d-SR may be obtained from Santa Cruz Biotechnology (Dallas, Tex., USA), and the antibody that recognizes both mSR and dSR may be purchased from Abeam, Inc. (Cambridge, Mass.). The primary antibody for β-actin is from Abeam. Immune reactive bands may be detected using the ECL Plus Western. Blotting Detection System (GE Healthcare, Piscataway, N.J., USA) and quantification may be accomplished by volume densitometry using ImageJ software (National Institutes of Health, Bethesda, MD) and normalization to β-actin.

[0141] Measurement of Cytokines Release from Primary Human Monocytes

[0142] Human primary monocytes are isolated (enriched) from buffy coats of healthy human blood donors. Cells are seeded in 24-well-plates for ELISA experiments. The results are normalized to LPS, provided as 100%, and presented as percentage of change cytokine levels. The various respective statistical significances are calculated by T-Test. The toxicity of the compounds on the cells is also tested using Alamar Blue. Treatment with toxic amounts of sodium fluoride (NaF at 250 μg/ml) are used as control.

[0143] Treatment of SARS-CoV-2 Positive Patients with the Herein Compounds

[0144] SARS-CoV-2 positive patients (typically, but not necessarily mild to severe patients) are evaluated for the presence of elevated plasma and/or saliva concentrations of pro-inflammatory agents (e.g., interleukins (IL), chemokines, granulocyte colony-stimulating stimulating factors (G-CSF), and/or tumor necrosis factor-α (TNF-α)), and optionally also other markers of systemic inflammation.

[0145] The patient's temperature, blood oxygen levels, respiration rate and other determinants of clinical status are determined. Patient anxiety and depression may be further assessed using the Hospital Anxiety and Depression Scale (HADS).

[0146] A pharmaceutical composition comprising one or more compounds according to Formula I-XIX is administered to the patient (optionally in a daily administration), and the plasma or saliva concentrations of the inflammatory markers, general clinical status, and anxiety and depression are monitored. A positive response is defined as reduced plasma/saliva concentrations of the pro-inflammatory agents, improved clinical status, and reduced anxiety and depression as measured by the HADS score. The pharmaceutical composition comprising one or more compounds according to Formula I-XIX may be administered via i.v. infusion, i.p. (intraperitoneal) administration, by intranasal, sublingual, or by oral administration, at an optional dose, below the normal anesthetic dose (e.g., 0.15 mg/kg-0.3 mg/kg, based on total body weight for maximum 20 mg every 6 hours).

[0147] While the present invention has been particularly described, persons skilled in the art will appreciate that many variations and modifications can be made. Therefore, the invention is not to be construed as restricted to the particularly described embodiments, rather the scope, spirit, and concept of the invention will be more readily understood by reference to the claims which follow.